{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-040755","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.386123+00:00","generated_at":"2026-05-31T05:27:36.863234+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BridgeBio halts CAH gene therapy after Phase 1/2 shows cortisol production but not transformative; cuts budget $50M+","bullets":["Phase 1/2 ADventure trial of BBP-631 in classic CAH: increased endogenous cortisol in all higher-dose patients (max change 6.6 µg/dL post-ACTH); well tolerated with no treatment-related SAEs.","BBP-631 achieved durable transgene activity: 55-fold avg increase in 11-deoxycortisol at highest doses; ≥50% reduction in 17-OHP in majority of patients.","Company discontinues BBP-631 development for CAH, citing data not meeting threshold for additional capital investment; budget cut >$50M.","BridgeBio seeking partnership opportunities for BBP-631 or next-gen CAH gene therapies; est. >75,000 CAH cases in US+EU.","CFO states reserving gene therapy for priority targets like Canavan disease; will work with FDA to accelerate Canavan therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-040755","json":"https://secwatch.observer/filing/0001140361-24-040755.json","markdown":"https://secwatch.observer/filing/0001140361-24-040755.md","text":"https://secwatch.observer/filing/0001140361-24-040755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124040755/0001140361-24-040755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124040755/ef20035749_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:27:36.863234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}